JAZZ Stock: Jazz Pharmaceuticals plc Stock Price, Analysis & Insights
Get live JAZZ stock price $229.63, comprehensive Jazz Pharmaceuticals plc stock analysis, charts, news, and expert forecast. Real-time JAZZ stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Jazz Pharmaceuticals plc is a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, serving patients across the United States, Europe, and ot...
Company Information
- CEO
- Renee D. Gala
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2800
Contact Information
- Website
- https://www.jazzpharma.com
- Address
- Waterloo Exchange
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 2087.6)
✓ Lower volatility stock (Beta: 0.33) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Jazz Pharmaceuticals plc shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Jazz Pharmaceuticals plc
- ⚠Investors should consider how Jazz Pharmaceuticals plc fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 2087.6) requires strong growth to justify
Market Cap
14.41B
P/E Ratio (TTM)
2087.55
Beta
0.33
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare JAZZ with peer companies:
- Price
- $98.03
- Market cap
- 6.43B
- Price
- $246.34
- Market cap
- 12.68B
- Price
- $17.16
- Market cap
- 4.85B
- Price
- $67.07
- Market cap
- 8.35B
- Price
- $70.50
- Market cap
- 8.36B
- Price
- $471.32
- Market cap
- 10.87B
- Price
- $90.00
- Market cap
- 6.83B
- Price
- $123.35
- Market cap
- 9.07B
- Price
- $11.67
- Market cap
- 199.62M
- Price
- $85.71
- Market cap
- 5.88B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.